Overcoming the Three-Disulfide-Bond Purification Barrier: Linaclotide Impurity Profiling and Deficiency Response Strategies

Linaclotide is a peptide drug composed of 14 amino acids. Due to its unique "three pairs of disulfide bonds" structure, it is highly prone to generating mismatched isomers and various complex impurities during synthesis and purification. In the face of increasingly stringent regulatory requirements from ICH and NMPA, how to accurately identify and control these impurities has become a critical pain point for pharmaceutical companies during submission filings and responding to "deficiency letters / requests for supplementary information."

Unique Spatial Conformation and Biochemical Mechanism

Linaclotide is the first guanylate cyclase-C (GC-C) agonist approved for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Developed by Ironwood Pharmaceuticals, it was approved by the US FDA in August 2012 (trade name Linzess®); in China, NMPA approved it on January 15, 2019 for adult IBS-C under the trade name LINZESS®, 290 μg strength, with AstraZeneca responsible for development and commercialization in Mainland China, Hong Kong, and Macao.

• Mechanism of Action: It acts predominantly locally in the gastrointestinal tract with minimal systemic absorption. By binding to GC-C receptors on the luminal surface of intestinal epithelial cells, linaclotide increases intracellular and extracellular cyclic guanosine monophosphate (cGMP) concentrations, which subsequently stimulates chloride and bicarbonate secretion into the intestinal lumen, increasing intestinal fluid secretion and accelerating transit, while also reducing visceral hypersensitivity.

  
  

Linaclotide

CAS: 851199-59-2

• Structural Features: Its amino acid sequence is H‑Cys‑Cys‑Glu‑Tyr‑Cys‑Cys‑Asn‑Pro‑Ala‑Cys‑Thr‑Gly‑Cys‑Tyr‑OH, molecular formula C₅₉H₇₉N₁₅O₂₁S₆, molecular weight approx. 1526.8, CAS No. 851199‑59‑2. Six cysteine (Cys) residues in the sequence form three pairs of intramolecular disulfide bonds (Cys1–Cys6, Cys2–Cys10, Cys5–Cys13). This compact spatial structure confers high biological activity and resistance to enzymatic degradation. In the intestinal lumen, its C-terminal tyrosine (Tyr) residue is readily hydrolyzed by carboxypeptidase A, removing the tyrosine to generate an active 13-amino-acid metabolite (des-tyrosine-linaclotide, i.e., MM-419447), which jointly contributes to the pharmacological effect.

  
  

Impurity Profile Challenges in Solid-Phase Peptide Synthesis

Correct folding of the "three pairs of disulfide bonds" represents the core barrier in linaclotide synthesis. Conventional oxidative folding processes are highly prone to generating various structurally similar impurities, posing significant challenges for downstream chromatographic purification and structural elucidation:

1. Mismatched and Multimeric Impurities: Due to the presence of multiple disulfide bonds, minor deviations in oxidative conditions can lead to disulfide bond mismatching (scrambled isomers) or intermolecular disulfide cross-linking to form dimers and multimeric impurities.

2. Degradation and Rearrangement Impurities: Under specific pH or oxidative environments, the peptide chain is susceptible to degradation and rearrangement side reactions, such as the formation of IMD impurities or Cys1-ketone impurities (Cys-1-α-ketone Linaclotide).

3. Isomers and Modified Impurities: Synthesis may be accompanied by chiral inversion producing diastereomers (e.g., D-Cys5 isomer), as well as derivatives such as glucose adducts that may form under the influence of specific formulations or excipients.

   
   

During the drug filing phase, regulatory agencies typically focus on qualitative and quantitative data for these impurities. It should be noted that from a rigorous technical classification perspective based on the ISO 17034 reference material system, compounds used for structural elucidation and quantification are defined as "Analytical Reference Materials," which differ from official "Reference Standards" compiled in pharmacopeias such as USP. Analytical reference materials with high purity and accurate value assignment serve as the cornerstone for establishing reliable HPLC methods, completing analytical method validation, and satisfying official requests for supplementary information ("deficiency letters").

Patent Expiration and Domestic Generic Competition: Impurity Reference Standards Become the Bottleneck

The core compound patent for linaclotide expired in January 2024, and multiple domestic pharmaceutical enterprises in China have initiated generic development for this product. It is foreseeable that whoever can systematically characterize and control the impurity profile first will seize the initiative in submission timelines.

In this race, the completeness and accuracy of impurity reference standards directly determine R&D and filing efficiency.

CATO Linaclotide Impurity Reference Standards

One-Stop Availability, Including Complete Deficiency-Letter Suites

To address the practical needs of linaclotide generic R&D and regulatory filings, Guangzhou CATO Chemical Technology Co., Ltd. (CATO) provides a comprehensive set of linaclotide impurity reference standards, covering all the aforementioned impurity origins. Among these, the most valuable for regulatory submissions is a dedicated suite of impurity reference standards directly responding to review deficiency letters—CATO has fully prepared the complete set of 15 standards.

▍Dedicated Deficiency-Letter Impurities: Complete Set of 15, Directly Addressing Regulatory Concerns

These impurities represent the "tough nuts" that regulatory reviewers ask companies to perform supplementary studies on and supply reference standards for. Notably, the vast majority share the exact same molecular formula with parent linaclotide (C₅₉H₇₉N₁₅O₂₁S₆)—they are isomers resulting from disulfide bond mismatching/isomerization, sequence rearrangement, or chiral inversion. Their chromatographic behaviors are extremely similar, making separation and characterization exceptionally difficult. Method validation and specification limit justifications can only stand on solid ground when reference standards with well-defined structures are obtained. This is precisely why review deficiency letters frequently focus on these impurities.

Among them, C4X-210640 has a molecular formula of C₅₉H₇₉N₁₅O₂₁S₇ (one extra sulfur atom compared to the parent drug), corresponding to a sulfur-adduct impurity; the remaining 14 are isomers of the parent drug. Most require ultra-low temperature storage at −80±5°C, imposing higher demands on manufacturing and stability control.

▍Supported by Common Structural Characterization Impurities

In addition to the deficiency-letter dedicated set, CATO simultaneously provides structurally characterized reference standards for deletion, insertion, deamidation, oxidation, dimerization/polymerization, and chiral isomerization impurities, forming a comprehensive impurity profiling toolbox:

Complete range of Linaclotide impurity standards, with full deficiency-letter suites available under one roof at competitive terms. Inquiries are welcome! Click Official Website Direct Link

Key Reference Sources

1. Qiu Z, et al. A New Regioselective Synthesis of the Cysteine-Rich Peptide Linaclotide. Molecules. 2023;28(3):1007. — Sequence, three pairs of disulfide linkages (Cys1–6/2–10/5–13), FDA approval https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9919235/

2. Bryant AP, et al. Linaclotide is a potent and selective guanylate cyclase C agonist… Life Sciences. 2010. — GC-C agonistic mechanism, local action, and low absorption https://www.sciencedirect.com/science/article/abs/pii/S0024320510001244

3. StatPearls (NCBI) / J Med Chem 2021 — Active metabolite MM-419447: C-terminal Tyr cleaved by carboxypeptidase A to form a 13-peptide, minimal systemic absorption following oral administration https://www.ncbi.nlm.nih.gov/books/NBK578208/

4. ChEBI / PubChem CID 16158208; ChemSpider — Molecular formula C₅₉H₇₉N₁₅O₂₁S₆, CAS 851199-59-2, sequence and disulfide bonds https://www.chemicalbook.com/ChemicalProductProperty_EN_CB82498818.htm

5. FDA / ChEMBL Drug Approval Records — FDA approval on 2012-08-30, trade name Linzess®, molecular weight 1526.8 Da; FDA label strengths 72/145/290 μg https://www.drugs.com/history/linzess.html ; http://chembl.blogspot.com/2012/09/new-drug-approvals-2012-pt-xvii.html

6. AstraZeneca China Official Press Release, 2019-01-15 — NMPA approval of LINZESS® (Linaclotide) launch in China, IBS-C indication, AstraZeneca China rights https://www.astrazeneca.com.cn/zh/media/press-releases/2019/_.html

7. Pharnexcloud — China approval numbers (NMPA Approval No. J20200012), strength 290 μg, MAH and manufacturer information https://www.pharnexcloud.com/zixun/sd_37009

8. CN-Healthcare / PharmCube — Core compound patent expired on 2024-01-24, four domestic generic developers in China https://www.cn-healthcare.com/articlewm/20231004/content-1611686.html

9. Pharnexcloud — Filing acceptance status for Linaclotide Capsules by Double-Crane Pharmaceutical (Hainan) and Sichuan Gowell Pharmaceutical https://www.pharnexcloud.com/zixun/sx_5282

10. CDE-related articles: Regulatory filing pathways for peptide drugs (chemically synthesized peptides ≤40 amino acids submitted under chemical drug pathways) and requirements for front-loading impurity quality control https://finance.sina.cn/stock/med/2023-10-14/detail-imzqznhu0196433.d.html